Glucose Health (GLUC) versus Its Rivals Head-To-Head Comparison

Glucose Health (OTCMKTS:GLUC) is one of 50 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it contrast to its competitors? We will compare Glucose Health to similar businesses based on the strength of its analyst recommendations, institutional ownership, earnings, profitability, valuation, risk and dividends.

Earnings and Valuation

This table compares Glucose Health and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Glucose Health	$540,000.00	-$420,000.00	-6.57
Glucose Health Competitors	$328.46 million	-$36.87 million	-8.79

Glucose Health’s competitors have higher revenue, but lower earnings than Glucose Health. Glucose Health is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Glucose Health and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Glucose Health	-75.00%	N/A	N/A
Glucose Health Competitors	-32.78%	-20.31%	-6.64%

Volatility and Risk

Glucose Health has a beta of 3.49, suggesting that its share price is 249% more volatile than the S&P 500. Comparatively, Glucose Health’s competitors have a beta of 1.07, suggesting that their average share price is 7% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Glucose Health and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glucose Health	0	0	0	0	N/A
Glucose Health Competitors	243	451	925	73	2.49

As a group, “Medicinals & botanicals” companies have a potential upside of 43.95%. Given Glucose Health’s competitors higher probable upside, analysts plainly believe Glucose Health has less favorable growth aspects than its competitors.

Institutional & Insider Ownership

16.1% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 21.6% of shares of all “Medicinals & botanicals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Glucose Health Company Profile

Glucose Health, Inc. engages in the formulation, manufacturing, marketing, and distribution of soluble fiber infused nutritional beverages. It offers soluble fiber infused powdered iced tea, and flavored drink mixes for pre-diabetic and diabetic persons under the GLUCODOWN brand in North America. The company was formerly known as Bio-Solutions Corp. and changed its name to Glucose Health, Inc. in November 2014. Glucose Health, Inc. was incorporated in 2007 and is based in Bentonville, Arkansas.